Shanghai Henlius Biotech Receives Approval for Phase 1 Clinical Trial of HLX3902 Trispecific Antibody for Advanced Prostate Cancer in Australia
Shanghai Henlius Biotech Announces Phase 1 Approval for HLX3...
Sign in to continue:
Shanghai Henlius Biotech Announces Phase 1 Approval for HLX3...
Great Wall Terroir Holdings Limited – Completion of Share Pl...
China Oil And Gas Group Announces Strategic Cooperation with...
Innovent Biologics: NMPA Approval for Sintilimab + Fruquinti...
China International Development Corporation Limited Announce...
Sunshine Lake Pharma Co., Ltd. Completes H Share Full Circul...
China Metal Resources Utilization Limited Announces Delay in...
Shenzhen International Holdings Limited Announces Scrip Divi...
Shenzhen International Holdings: 2025 Final Dividend & Scrip...
VTech Holdings FY2026 Annual Results: In-Depth Investor Anal...